Last reviewed: June 21, 2026

Last updated: June 21, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Semaglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist originally developed for type 2 diabetes that has demonstrated significant weight-loss benefits in clinical populations. The medication works by mimicking a natural hormone that regulates appetite and blood sugar, leading to sustained reductions in calorie intake and body weight. PlexusDx delivers compounded semaglutide injections through licensed 503A pharmacies, making personalized GLP-1 therapy accessible across all 50 states without insurance.

How Semaglutide Works for Weight Loss

Semaglutide activates GLP-1 receptors in the brain regions responsible for appetite control, hunger sensation, and fullness signals. When you take semaglutide, your body releases less ghrelin (the hunger hormone) and increases peptide YY, which signals satiety to your central nervous system. This dual mechanism reduces your desire to eat, decreases snacking between meals, and increases the amount of food needed to feel satisfied.

The medication also slows gastric emptying—the rate at which food moves from your stomach into your small intestine. This extended stomach residence time creates a prolonged feeling of fullness after smaller meals, making it easier to maintain a calorie deficit without constant hunger or deprivation. Over weeks of consistent use, this physiologic shift supports sustainable weight loss without extreme dietary restriction.

Clinical Evidence for Semaglutide Weight Loss Results

The STEP (Semaglutide Treatment Effect in People with obesity) clinical trials demonstrated that people receiving semaglutide achieved average weight loss of 10-15% of baseline body weight compared to 2-3% in placebo groups. In the STEP 3 trial, participants maintained weight loss over 68 weeks, and continued treatment prevented weight regain during an additional maintenance phase. These results represent clinically meaningful improvements in cardiovascular risk factors, mobility, and metabolic health markers.

Real-world data from compounding pharmacy patients shows similar outcomes, with most individuals experiencing noticeable appetite reduction within 1-2 weeks and measurable weight loss by 4-6 weeks of consistent use. Individual results vary based on genetics, baseline metabolic rate, diet quality, physical activity, and adherence to the prescribed protocol. PlexusDx offers the Precision Peptide Genetic Test to identify genetic predispositions in pathways like GLP1R and FTO, helping predict your individual response potential.

Semaglutide Dosing and Dose Escalation Strategy

Semaglutide therapy begins at a low starting dose to allow your body to adjust and minimize side effects, then increases gradually over several weeks in a structured titration schedule. Your provider adjusts your dose upward based on your tolerance, appetite suppression response, and weight-loss progress—not based on body weight or BMI thresholds. This personalized approach ensures you find your effective dose while maintaining tolerability.

PlexusDx compounds semaglutide injections at a flat monthly price of $149 at the starting tier, regardless of which dose level you eventually reach. Your dose may need to go up as your body adjusts, but your price won't increase—this ensures that dose optimization never becomes a financial barrier to reaching your target weight-loss outcome. Injection pens or syringes are administered once weekly, either by yourself or with provider guidance.

Managing Side Effects and Optimizing Your Weight Loss Journey

Common side effects during the first 2-4 weeks include mild nausea, reduced appetite for favorite foods, changes in bowel regularity, and fatigue. These effects typically diminish as your body adapts, though some people experience persistent mild nausea if their dose escalates too quickly. Eating smaller, frequent meals of protein-rich and hydration-focused foods, plus staying well-hydrated throughout the day, significantly reduces GI discomfort and supports consistent weight loss.

PlexusDx patients receive ongoing support from licensed providers who monitor your progress, adjust your dose safely, and help troubleshoot side effects or plateaus. The Precision Peptide Genetic Test identifies your individual peptide-pathway variations across 49 peptides and 14 metabolic pathways, allowing your provider to predict which GLP-1 therapy or combined peptide approach may work best for your unique biology. This personalization increases both efficacy and tolerability, making your weight-loss experience more predictable and sustainable.

PlexusDx Compounded Semaglutide vs. Brand Wegovy: Access and Affordability

PlexusDx sources semaglutide from licensed 503A compounding pharmacies, which compound the medication in-house to exact specifications and ship directly to patients across all 50 states. This model eliminates insurance gatekeeping, prior authorization delays, and supply shortages that often limit access to brand-name Wegovy. PlexusDx compounded semaglutide starts at $149 per month with no membership fee, no insurance requirement, and full HSA/FSA eligibility.

Both compounded and brand semaglutide use the same active pharmaceutical ingredient and work through identical biological mechanisms; the primary difference is access, cost, and personalization. PlexusDx adds genetic testing and provider-guided dose optimization at the same flat price, ensuring you receive the most effective dose for your body without paying more as your therapy advances. If you have insurance coverage for Wegovy, PlexusDx remains an affordable backup option; if you don't have coverage, PlexusDx makes GLP-1 therapy immediately available without prior authorization or insurance appeals.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

How long does it take to see weight loss results with semaglutide?

Most PlexusDx patients notice reduced appetite and food cravings within 1-2 weeks of starting semaglutide injections. Measurable weight loss typically becomes visible on the scale by week 4-6, with steady monthly losses of 2-4 pounds. Results accelerate as your dose reaches therapeutic levels and your body fully adapts to the medication's appetite-suppressing effects.

What percentage of weight can you expect to lose with semaglutide?

Clinical trials show average weight loss of 10-15% of your starting body weight over 68 weeks of semaglutide therapy. Some individuals lose up to 20% or more, while others achieve 8-10% losses depending on genetics, diet quality, exercise, and adherence. PlexusDx Precision Peptide Genetic Testing helps predict your individual response potential based on your GLP1R, GIPR, FTO, and MC4R genetic variants.

Does PlexusDx compounded semaglutide cost more as your dose increases?

No. PlexusDx charges a flat monthly rate starting at $149 for compounded semaglutide injections, regardless of your dose level. Your dose may need to go up as treatment progresses, but your price won't—this pricing model ensures dose optimization is never blocked by cost concerns.

Is compounded semaglutide safe, and does it work as well as brand Wegovy?

PlexusDx sources compounded semaglutide from licensed 503A compounding pharmacies regulated by state boards and the FDA. Compounded semaglutide contains the identical active ingredient as Wegovy and produces equivalent appetite suppression and weight loss when dosed appropriately. The main differences are access speed and affordability—PlexusDx delivers therapy without insurance requirements or prior authorization delays.

How does the Precision Peptide Genetic Test help predict my semaglutide results?

PlexusDx Precision Peptide Genetic Testing ($99 add-on after your first month) analyzes 14 metabolic pathways and identifies key variants in your GLP1R, GIPR, FTO, and MC4R genes. These variants predict your appetite-regulation biology and baseline response to semaglutide, allowing your provider to optimize your dose strategy and determine if combined peptide therapy (like GLP-Squared) may enhance your weight-loss outcome.

Related Reading

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.

Real prescribers. Published prices. No surprises.

Licensed providers in all 50 states. Online intake. No insurance, no membership required.

Start My Intake

~60 seconds · $0 charged until your provider approves